The study has a selection bias, because 40.8% of the patients included have experienced prior treatments. Likewise, patients with an ophthalmic history of other disease that could affect vision, such as age-related macular degeneration and diabetic retinopathy, were not excluded. On the other hand, re-treatment with dexamethasone implant (DEX implant, Ozurdex; Allergan, Inc., Irvine, CA, USA), the use of other retinal vein occlusion (RVO) therapies in addition to DEX implant, and evaluations of the examinations were at the discretion of the treating physician. Although the best-corrected visual acuity (BCVA) in the study eye ranged from Bhand motion^and Bfinger counting^to better than 20/20 Snellen, yet 27 patients with best visual function determined as Bcount fingers^or Bhand motion^were excluded from the analysis of BCVA. These patients should have been included in the study after conversion of Snellen BCVA to logarithm of the minimal angle of resolution (LogMAR) and to approximate Early Treatment Diabetic Retinopathy Study letters. The rate of discontinuations or losses of follow-up was too large. At week 24, BCVA and optical coherence tomography were not evaluated to 44.9% and 58.3% of the patients respectively.
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In the assessment of the 6-month results, we considered the current assertion [2] according to which evaluation of outcomes should be guided by the anatomic data with visual changes as a secondary guide. Despite a gain of approximately 5 letters in BCVA score, the central retinal thickness (CRT) improved to 411 μm, a value which is much more than the cutoff for the upper level of normal CRT plus two standard deviations [3, 4] . The persistence of high values of the CRT after treatment highlights unresolved macular edema (ME), and indicates that the disease process is still active and progressive, requiring further treatment with anti-angiogenic agents.
The unsatisfactory results of this series could be explained by the low frequency of injections and the longstanding duration of ME (approximately 3 months). A mean of 1.17 DEX implant injections during the study period was insufficient to stabilize the ME and denoted that the authors did not take into consideration the currently valid recommendations, that the duration of ≥ 3-line improvement after DEX implant is typically 2-3 months [5] , and that reinjections generally will be performed after 4-5 months [6] .
Our group published a prospective clinical study [7] on the 3-year results of bevacizumab (Avastin; Genentech Inc., South San Francisco, CA, USA) treatment in patients with acute (≤1 month after the occlusion was diagnosed) central/ hemicentral retinal vein occlusions (central/hemicentral RVOs) showing, for the first time, evidence suggesting that early treatment applied immediately after the clinical onset of venous occlusion provided significant and sustained improvements in BCVA and CRT with inactive disease in most phakic patients with acute central/hemicentral RVOs, making this treatment option a rational and viable therapeutic strategy.
Altogether, regardless of the intravitreal pharmacotherapy chosen, namely, specific (bevacizumab/ranibizumab [Lucentis; Genentech Inc.]/aflibecept [Eylea, Regeneron Pharmaceuticals, Tarrytown, NY, USA]) or nonspecific (DEX implant) anti-VEGF agents, the efficacy of treatment depends primarily on the promptness of the therapy after RVO onset [8, 9] . Both groups of anti-VEGF substances provide similar rates of vision improvement using the current algorithms for administration [5] [6] [7] , but with superior anatomic outcomes and fewer injections in the DEX implant-treated eyes. However, more patients receiving the DEX implant lose vision mainly due to cataract. Percentage of eyes considered Bdry^on OCT as per criterion of CRT < 320 μm [4] or <250 [3] μm at the end of the study (month 6)
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